SUPERNUS PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Insider Trading Arrangements and Policies
The table below lists the insider trading arrangements adopted or terminated during the fourth quarter of 2025.
| Name and Title of Director or Officer | Rule 10b5-1 Trading Arrangement(1) | Trading Arrangement Adopted or Terminated | Date of Adoption or Termination | Duration of Trading Arrangement | Aggregate Number of Securities to be Purchased Pursuant to Trading Arrangement | Aggregate Number of Securities to be Sold Pursuant to Trading Arrangement |
|---|---|---|---|---|---|---|
| Jack KhattarPresident, Chief Executive Officer and Director | Yes | Adopted | December 12, 2025 | First Transaction Date through February 22, 2029 | — | 322,500(2)(3) |
| Padmanabh BhattSVP, Chief Scientific Officer, Intellectual Property | Yes | Adopted | December 15, 2025 | First Transaction Date through May 31, 2026 | — | 107,250(2) |
(1) Indicates whether the trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
(2) This trading arrangement covers the exercise and sale of stock options, with such sales limited to an amount reasonably estimated such that the net proceeds from the sale are sufficient to cover the exercise cost and taxes associated with the exercise of the stock options.
(3) This includes 35,000 sale of common stock which are indirectly beneficially owned by Jack Khattar through the KBT Trust.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.